Guy's and St Thomas' NHS Trust Expands Advanced Therapy Manufacturing Capacity by 60% to Meet Growing Cell and Gene Therapy Demand
核心洞察
Guy's and St Thomas' NHS Foundation Trust is expanding its Advanced Therapy Manufacturing Platform with two new ISO Class 7 cleanrooms to increase production capacity by up to 60%.
The facility expansion will accommodate a broader portfolio of advanced therapies including stem cell-derived photoreceptors (搜索) and adherent cell products (搜索) beyond its current regulatory T-cell immunotherapy (搜索) work.
The project involves complex construction within an operational hospital environment while maintaining patient care and includes Grade A processing areas with enhanced material flow systems.
Guy's and St Thomas' NHS Foundation Trust (GSTT) is significantly expanding its Advanced Therapy Manufacturing Platform to address the rising demand for clinical trial production of cell and gene therapies. The expansion, delivered in collaboration with the NIHR Maudsley Biomedical Research Centre (搜索) at King's College London, will increase production capacity by up to 60%.
Facility Enhancement Details
The Clinical Research Facility GMP Unit (CRF GMP Unit) serves as a dedicated cleanroom environment for manufacturing Investigational Medicinal Products (搜索) (IMPs) and unlicensed Specials for clinical trials. Currently recognized for its regulatory T-cell immunotherapy (搜索) work, the unit is scaling up to accommodate a wider portfolio of advanced therapies, including stem cell-derived photoreceptors (搜索) and adherent cell products (搜索).
The expansion includes the addition of two new ISO Class 7 cleanrooms and Grade A processing areas equipped with Class II Biosafety Cabinets or isolators. Enhanced material flow systems, controlled storage, and improved waste handling capabilities are integral components of the upgrade.
Technical Infrastructure and Design
Cleanroom design and engineering specialist Scitech (搜索) has supported the project from concept through full detailed design and into the final construction stages. The company's scope included designing cleanrooms capable of full-room biodecontamination, integrating CO₂ and compressed air infrastructure, and implementing controlled access with electronic pressure monitoring.
The facility layout ensures segregated flows for personnel and materials, maximizing GMP efficiency and regulatory compliance while enabling cost-effective delivery of Advanced Therapy Medicinal Products (搜索) (ATMPs). The design achieves compliance with UK and EU regulatory frameworks for clinical trial manufacturing.
Construction Challenges in Live Hospital Environment
The project presents unique logistical challenges as construction occurs within the operational 15th floor of a live hospital building. This requires close coordination with NHS staff and departments to minimize disruption to patient care and ensure safety during construction.
"The onsite coordination has been to the millimetre, one of the most complex threading of utilities we have done, to fit into the space available," said a Scitech (搜索) spokesperson. "The work has been carried out safely on the 15th floor of an operational building with patients, families, doctors, and NHS staff working in rooms around, above, and below the site."
Impact on UK Advanced Therapy Capabilities
The upgraded facility is expected to significantly enhance the Trust's capacity to support clinical research and manufacture GMP-compliant therapies for a growing pipeline of advanced treatments. This expansion reinforces GSTT's position at the forefront of advanced therapy manufacturing and strengthens the UK's capabilities in delivering innovative therapies for clinical trials.
The facility serves as a critical infrastructure component for the UK's advanced therapy sector, supporting the development and clinical testing of next-generation cell and gene therapies that represent the future of personalized medicine.